Package Leaflet: Information for the User
Emconcor 10 mg Film-Coated Tablets
Bisoprolol Fumarate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
The active substance in Emconcor is bisoprolol. Bisoprolol belongs to a group of medicines called beta-blockers. These medicines work by affecting the body's response to certain nerve impulses, especially in the heart. As a result, bisoprolol slows down the heart rate and makes the heart more efficient at pumping blood throughout the body. At the same time, it reduces the heart's need for blood and oxygen.
Emconcor is used to treat high blood pressure and chronic stable angina.
Do not take Emconcor
Do not take Emconcor if you have any of the following conditions:
Do not take Emconcor if you have any of the following heart problems:
Warnings and precautions
If you have any of the following conditions, tell your doctor before taking Emconcor:
In addition, tell your doctor if you are going to undergo:
Children and adolescents
Emconcor is not recommended for use in children and adolescents.
Using Emconcor with other medicines
Tell your doctor or pharmacist that you are taking, have recently taken, or might take any other medicines.
Do not take the following medicines with Emconcor without special advice from your doctor:
Consult your doctor before taking the following medicines with Emconcor; your doctor may need to monitor your condition more frequently:
Pregnancy and breastfeeding
There is a risk that using Emconcor during pregnancy may harm the baby.
If you are pregnant or planning to become pregnant, tell your doctor. Your doctor will decide whether you can take Emconcor during pregnancy.
It is not known whether Emconcor passes into human breast milk. Breastfeeding is not recommended during treatment with Emconcor.
Driving and using machines
Your ability to drive or use machines may be affected depending on how you tolerate the medicine. Be especially careful at the start of treatment and when changing doses or medication, and also when combined with alcohol.
Important information about some of the ingredients of Emconcor
Athletes are informed that this medicine contains a component that may result in a positive doping test.
Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Treatment with Emconcor should be started gradually with low doses, which should be increased gradually. In all cases, the dose should be adjusted individually, particularly according to heart rate and therapeutic success.
Dosage
For both indications, the normal dose is one Emconcor 5 mg or half a tablet of Emconcor 10 mg (equivalent to 5 mg of bisoprolol) once a day.
If necessary, the dose can be increased to one Emconcor 10 mg tablet or two Emconcor 5 mg tablets (equivalent to 10 mg of bisoprolol) once a day.
The maximum recommended dose is 20 mg once a day.
Duration of treatment
Treatment with Emconcor is usually long-term.
Dosage in case of hepatic or renal impairment
In patients with mild to moderate hepatic or renal impairment, no dose adjustment is normally required. In patients with severe renal impairment (creatinine clearance <20 ml min) and in patients with severe hepatic impairment, the daily dose should not exceed 10 mg.< p>
Dosage in the elderly
No dose adjustment is required in the elderly.
Method of administration
Take the tablet with a little water in the morning, with or without food. Do not crush or chew the tablet.
If you take more Emconcor than you should
If you have taken more Emconcor than you should, tell your doctor immediately. Your doctor will decide what actions are necessary.
The symptoms of an overdose include slow heart rate (bradycardia), difficulty breathing (bronchospasm), severe low blood pressure, acute heart failure, or low blood sugar levels.
In case of overdose or accidental ingestion, contact the Toxicology Information Service: Tel. 91.562.04.20.
If you forget to take Emconcor
Do not take a double dose to make up for forgotten doses. Take your usual dose the next morning.
If you stop taking Emconcor
Never stop taking Emconcor except on the advice of your doctor. Otherwise, your condition may worsen. Treatment should not be stopped abruptly, especially in patients with ischaemic heart disease. If you need to stop treatment, your doctor will tell you how to reduce the dose gradually.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Emconcor can cause side effects, although not everybody gets them.
These side effects are listed below according to their frequency of possible occurrence:
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
If you experience any side effects, talk to your doctor or pharmacist, even if it is not listed in this leaflet.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
No special storage conditions are required.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Emconcor
Tablet core: anhydrous colloidal silica, magnesium stearate, crospovidone, microcrystalline cellulose, maize starch, anhydrous calcium hydrogen phosphate.
Coating: titanium dioxide (E 171), macrogol 400, dimeticone, yellow iron oxide (E 172), hypromellose.
Appearance of the product and pack contents
Emconcor 10: Orange, scored, coriform tablets.
Packs of 60 tablets.
Marketing authorisation holder and manufacturer:
Marketing authorisation holder:
Merck, S.L.
María de Molina, 40
28006, Madrid
Spain
Manufacturer:
Merck Healthcare KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
or
Merck, S.L.
Merck Industrial Estate, 08100
Mollet del Vallés (Barcelona)
Spain
Date of last revision of this leaflet: 11/2020
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/